FY2025 EPS Forecast for PTC Therapeutics Lifted by Analyst

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for PTC Therapeutics in a report issued on Wednesday, November 5th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn $9.04 per share for the year, up from their prior estimate of $7.49. Cantor Fitzgerald currently has a “Overweight” rating and a $118.00 price target on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. Cantor Fitzgerald also issued estimates for PTC Therapeutics’ FY2026 earnings at ($2.72) EPS.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The company had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS.

Several other research firms have also recently issued reports on PTCT. UBS Group upped their price objective on PTC Therapeutics from $71.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Bank of America decreased their target price on PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th. Royal Bank Of Canada upped their price target on PTC Therapeutics from $70.00 to $82.00 and gave the company an “outperform” rating in a report on Wednesday. Barclays increased their price target on shares of PTC Therapeutics from $46.00 to $68.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Citigroup boosted their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $75.40.

PTC Therapeutics Trading Down 1.1%

Shares of PTCT opened at $71.78 on Friday. The firm has a market capitalization of $5.70 billion, a price-to-earnings ratio of 10.30 and a beta of 0.60. The firm’s fifty day simple moving average is $63.31 and its 200-day simple moving average is $53.60. PTC Therapeutics has a twelve month low of $35.95 and a twelve month high of $73.98.

Insider Buying and Selling

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 3,375 shares of the business’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $63.43, for a total value of $214,076.25. Following the transaction, the vice president directly owned 103,901 shares of the company’s stock, valued at approximately $6,590,440.43. The trade was a 3.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Allan Steven Jacobson sold 12,000 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $65.00, for a total transaction of $780,000.00. Following the transaction, the director owned 17,451 shares of the company’s stock, valued at approximately $1,134,315. The trade was a 40.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 254,662 shares of company stock valued at $16,000,821 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On PTC Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in PTC Therapeutics by 86.3% in the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 441 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of PTC Therapeutics during the 1st quarter worth approximately $524,000. Banque Pictet & Cie SA acquired a new stake in shares of PTC Therapeutics in the 1st quarter valued at approximately $342,000. Cerity Partners LLC purchased a new stake in shares of PTC Therapeutics in the first quarter valued at approximately $641,000. Finally, Xponance Inc. boosted its stake in shares of PTC Therapeutics by 5.2% in the first quarter. Xponance Inc. now owns 6,372 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 314 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.